Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth.

Slides:

Advertisements

Similar presentations

Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice Michelle Nisolle, M.D., Ph.D., Françoise Casanas-Roux, B.S.,

Advertisements

Carlos Morán, M. D. , Eric Knochenhauer, M. D. , Larry R Boots, Ph. D

Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind,

Volume 149, Issue 1, Pages (March 2000)

Héctor F Escobar-Morreale, M. D. , Ph. D

A powerful new agonist: flooding the system with growth hormone

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial Dana A. Muin, M.D., M.Sc.,

Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis Paolo Vercellini, M.D., Giussy Barbara, M.D., Edgardo Somigliana,

Divergent effects of a combined hormonal oral contraceptive on insulin sensitivity in lean versus obese women Kai I. Cheang, Pharm.D., M.S., Paulina.

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Infertility evaluation and treatment among women in the United States

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route Sanna Kallio, M.D., Johanna Puurunen,

Dennis J. Hand, Ph. D. , Vanessa L. Short, Ph. D. , M. P. H. , Diane J

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone.

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids Isabelle.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women Raymond W Ke,

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause Chris M.G. Thomas, Ph.D.,

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy Concepción Ceballos, Constantino Ribes,

A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome Dorte Glintborg, M.D., Ph.D.,

Growth hormone, insulin-like growth factor I, and leptin interaction in human cultured lutein granulosa cells steroidogenesis Maria Karamouti, M.D, Panagoula.

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Caring for adolescent renal patients

Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro.

Claudia Bohring, Ph.D., Jan Skrzypek, M.D., Walter Krause, M.D.

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Mohamed A.M Hassan, M.Sc., Stephen R Killick, M.D.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Low-dose hormone therapy and carbohydrate metabolism

Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Ettore Cicinelli, M. D. , Louis J Ignarro, M. D. , Pietro Galantino, M

Effects of nonoral estradiol–micronized progesterone or low-dose oral estradiol– drospirenone therapy on metabolic variables and markers of endothelial.

Correlations between concentrations of interleukin-12 and interleukin-13 and lymphocyte subsets in the follicular fluid of women with and without polycystic.

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

Noha H Farag, M. D. , Scott C Matthews, M. D. , Eva Brzezinski, M. S

Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies Gene A Hines, Ph.D., Elizabeth R Smith, B.S., Ricardo.

Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women.

Pyridostigmine cotreatment for controlled ovarian hyperstimulation in low responders undergoing in vitro fertilization–embryo transfer Chung-Hoon Kim,

Naloxone decreases insulin secretion in hyperinsulinemic postmenopausal women and may positively affect hormone replacement therapy Francesco Cucinelli,

Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women Hong Zang, M.D., Kjell Carlström,

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind,

Effects of patch or gel estrogen therapies on auditory brainstem response in surgically postmenopausal women: a prospective, randomized study Salvatore.

Antecubital vein venous sampling does not distort circulating levels of peptide and sex steroid hormones Michael P. Diamond, M.D., Michael Kruger, M.S.,

Effects of hyperglycemia on the differential expression of insulin and insulin-like growth factor-I receptors in human normal peritoneal and adhesion.

High serum concentration of total inhibin in polycystic ovary syndrome

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Dijana Hadžiomerović, M. D. , Bernhard Rabenbauer, M. D

Obesity and androgens: facts and perspectives

Anuja Dokras, M. D. , Ph. D. , Antonia Habana, M. D. , Juan Giraldo, M

Dehydroepiandrosterone: a springboard hormone for female sexuality

Olav Istre, M.D., Ph.D., Birgitta Trolle, M.D. Fertility and Sterility

George Christodoulakos, M. D. , Irene Lambrinoudaki, M. D

Low-dose conjugated equine estrogens elevate circulating neurotransmitters and improve the psychological well-being of menopausal women Arturo Zárate,

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Hormones, mood, sexuality, and the menopausal transition

Thomas M Price, M.D., Susan Allen, R.N., G.Vernon Pegram, M.D.

Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic.

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Norbert.

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3 Wendy Chang, M.D.,

Stephen J Winters, M. D. , Evelyn Talbott, David S Guzick, Ph. D. , M

Presentation transcript:

Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women Alessandro D Genazzani, M.D., Ph.D., Massimo Stomati, M.D., Claudia Strucchi, M.D., Simone Puccetti, M.D., Stefano Luisi, M.D., Andrea R Genazzani, M.D. Fertility and Sterility Volume 76, Issue 2, Pages 241-248 (August 2001) DOI: 10.1016/S0015-0282(01)01902-1

Figure 1 Growth hormone response to the GHRH stimulation test in the four groups of women under study. (A), Lean postmenopausal women, aged 50 to 55 years. (B), Lean postmenopausal women, aged 60 to 65 years. (C), Overweight postmenopausal women, aged 50 to 55 years. (D), Overweight postmenopausal women, aged 60 to 65 years. Profiles of GH response appear relatively modified by the DHEA administration. ■ Before treatment; ▴ Sixth month of treatment. Genazzani. DHEA administration modulates the GHRH-GH-IGF-J axis. Fertil Steril 2001. Fertility and Sterility 2001 76, 241-248DOI: (10.1016/S0015-0282(01)01902-1)

Figure 2 GH response to GH-RH expressed as mean Δ in Group A (lean postmenopausal women), Group B (obese postmenopausal women), Group C (lean, late postmenopausal women), and Group D (obese, late postmenopausal women). (A), Baseline. (B), Mean percent variation. (C), Mean maximum GH response. The different way of representing the response of GH might condition data interpretation even if it appears clear that aging and obesity induce a lower response of GH to GHRH (panels A to B). The dotted bar is before treatment; the stripped bar is the sixth month of treatment. ∗∗P <.01 vs. all groups; ∗P <.05 vs. before treatment Genazzani. DHEA administration modulates the GHRH-GH-IGF-I axis. Fertil Steril 2001. Fertility and Sterility 2001 76, 241-248DOI: (10.1016/S0015-0282(01)01902-1)

Figure 3 IGF-1 response to the GHRH stimulation test in the four groups of women under study. (A), Lean postmenopausal women, aged 50 to 55 years. (B), Lean postmenopausal women, aged 60 to 65 years. (C), Overweight postmenopausal women, aged 50 to 55 years. (D), Overweight postmenopausal women, aged 60 to 65 years. The profiles of IGF-1 response appear to be scarcely modified by the DHEA administration. ■ Before treatment; ▴ sixth month of treatment. Genazzani. DHEA administration modulates the GHRH-GH-IGF-I axis. Fertil Steril 2001. Fertility and Sterility 2001 76, 241-248DOI: (10.1016/S0015-0282(01)01902-1)

Figure 4 IGF-1 response to GHRH expressed as (A), mean Δ from baseline values, (B), mean percentage variation, or (C), mean maximum GH response in the early postmenopausal lean (Group A) and obese (Group B) and late postmenopausal lean (Group C) and obese (Group D) women. The different way of representing the response of IGF-1 might condition data interpretation. Only obese early postmenopausal women showed a significant IGF-1 Δ (A). DHEA administration influenced IGF-1 response to GH-RH increasing IGF-1 plasma levels more than the entity of the response, because the IGF-1 response minimally changed (A–B). Maximum IGF-1 responses were obviously increased (C). Dotted bar is before treatment; stripped bar is sixth month of treatment. ∗P <.05 or ∗∗P <.01 vs. before treatment. Genazzani. DHEA administration modulates the GHRH-GH-IGF-I axis. Fertil Steril 2001. Fertility and Sterility 2001 76, 241-248DOI: (10.1016/S0015-0282(01)01902-1)